|
|
|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 22:06
|
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results (Business Wire)
|
|
|
Confident in China Progress and Future Roadmap
A Clear Path Toward Sustainable Profitability and Growth
Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation
STAAR Interim co-CEOs Issue Letter to Shareholders
Earnings Call and Webcast Today at 5:30 PM EasternLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases.
Fourth Quarter 2025 Financial Overview
Net sales of $57.8 million, up 18.1% Y/Y
Net sales excluding China of $40.3 million, down 2.1% Y/Y
Gross margin at 75.7% vs. 64.7% Y/Y
Net loss of $(18.3) million or $(0.37) per share, compared to a net loss of $(34.2) mi...
|
|
|
|
|
23.02.26 - 22:03
|
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026 (Business Wire)
|
|
|
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress.
Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast
Date: Tuesday, March 3, 2026
Time: 5:30 p.m. ET/ 2:30 p.m. PT
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd
Topics on the call will include:
Review of Fiscal Year 2025 Operations and Financial Results
China Recovery and Operational Improvements
Inventory Normalization
Cost Discipline
Update on Manufacturing Expansion in Switzerland
Innovation Pipeline Progress
2026 Strategic Focus
The live webcast, including ...
|
|
|
|
|
|
|
02.02.26 - 13:03
|
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs (Business Wire)
|
|
|
Search Committee Has Initiated a Global Search to Select Next CEOLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the “Board”) has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.
“Warren and Deborah are respected and qualified leaders with deep knowledge of STAAR and our industry. The entire Board is confident in their ability to ensure business continuity and lead our Company during this period of transition,” said Neal C. Bradsher, Chairman...
|
|
|
|
|
|
|
15.01.26 - 14:39
|
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement (Business Wire)
|
|
|
Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board
STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board
Farrell will Remain CEO until January 31, 2026LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates (“Broadwood”), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5% of STAAR's outstanding common stock, have joined STAAR's Board of Directors (the “Board”), effective immediately.
These changes were made in connection with a cooperation agreement entered into between the Company and Broadwood (the “Cooperation Agreement”). As p...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
